TScan Therapeutics Inc (TCRX)
TScan Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. Co.'s proprietary platform is designed to: discover anti-cancer TCRs from patients with exceptional responses to immunotherapy; discover TCRs that recognize clinically validated targets; identify off-targets of TCRs to eliminate candidates; and manufacture TCR-T therapies using Co.'s T-Integrate technology. The central elements of Co.'s platform that differentiate it from other cell therapy companies are TargetScan, ReceptorScan, SafetyScan, ImmunoBank and T-Integrate.
| Company Name: |
TScan Therapeutics Inc |
| Website: |
www.tscan.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding TCRX: |
4 |
| Total Market Value Held by ETFs: |
$18.22M |
| Total Market Capitalization: |
$335.00M |
| % of Market Cap. Held by ETFs: |
5.44% |
|
|
May 2, 2024 • 9:50 AM Eastern
Strong Buy (4.00 out of 4)
78th percentile
|
|
Free TCRX Email Alerts:
